vs
Antero Midstream Corp（AM）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Antero Midstream Corp的1.9倍（$540.7M vs $291.1M），Antero Midstream Corp净利率更高（41.5% vs -2.9%，领先44.4%），Antero Midstream Corp同比增速更快（-7.3% vs -14.1%），Antero Midstream Corp自由现金流更多（$186.9M vs $36.0M），过去两年Antero Midstream Corp的营收复合增速更高（3.9% vs -2.3%）
Antero Midstream Corp是美国能源企业，注册地为特拉华州，总部设于科罗拉多州丹佛市。公司全部油气储量均位于阿巴拉契亚盆地，采用水力压裂技术开采，核心业务涵盖油气勘探开发相关领域。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
AM vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.9倍
$291.1M
营收增速更快
AM
高出6.8%
-14.1%
净利率更高
AM
高出44.4%
-2.9%
自由现金流更多
AM
多$150.9M
$36.0M
两年增速更快
AM
近两年复合增速
-2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $291.1M | $540.7M |
| 净利润 | $120.7M | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | 60.9% | 1.0% |
| 净利率 | 41.5% | -2.9% |
| 营收同比 | -7.3% | -14.1% |
| 净利润同比 | 2.1% | 34.0% |
| 每股收益（稀释后） | $0.25 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMICUI
| Q1 26 | $291.1M | — | ||
| Q4 25 | $297.0M | $540.7M | ||
| Q3 25 | $294.8M | $537.0M | ||
| Q2 25 | $305.5M | $548.9M | ||
| Q1 25 | $291.1M | $604.7M | ||
| Q4 24 | $287.5M | $629.8M | ||
| Q3 24 | $269.9M | $589.1M | ||
| Q2 24 | $269.8M | $596.5M |
净利润AMICUI
| Q1 26 | $120.7M | — | ||
| Q4 25 | $51.9M | $-15.7M | ||
| Q3 25 | $116.0M | $-3.4M | ||
| Q2 25 | $124.5M | $35.3M | ||
| Q1 25 | $120.7M | $-15.5M | ||
| Q4 24 | $111.2M | $-23.8M | ||
| Q3 24 | $99.7M | $-33.0M | ||
| Q2 24 | $86.0M | $-21.4M |
毛利率AMICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 34.7% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.8% |
营业利润率AMICUI
| Q1 26 | 60.9% | — | ||
| Q4 25 | 33.8% | 1.0% | ||
| Q3 25 | 61.2% | 2.6% | ||
| Q2 25 | 61.0% | 1.9% | ||
| Q1 25 | 60.9% | 2.1% | ||
| Q4 24 | 61.8% | 6.0% | ||
| Q3 24 | 60.2% | 1.4% | ||
| Q2 24 | 56.6% | 1.3% |
净利率AMICUI
| Q1 26 | 41.5% | — | ||
| Q4 25 | 17.5% | -2.9% | ||
| Q3 25 | 39.3% | -0.6% | ||
| Q2 25 | 40.8% | 6.4% | ||
| Q1 25 | 41.5% | -2.6% | ||
| Q4 24 | 38.7% | -3.8% | ||
| Q3 24 | 37.0% | -5.6% | ||
| Q2 24 | 31.9% | -3.6% |
每股收益（稀释后）AMICUI
| Q1 26 | $0.25 | — | ||
| Q4 25 | $0.11 | $-0.63 | ||
| Q3 25 | $0.24 | $-0.14 | ||
| Q2 25 | $0.26 | $1.43 | ||
| Q1 25 | $0.25 | $-0.63 | ||
| Q4 24 | $0.23 | $-0.97 | ||
| Q3 24 | $0.21 | $-1.35 | ||
| Q2 24 | $0.18 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.4M | — |
| 总债务越低越好 | $3.2B | — |
| 股东权益账面价值 | $2.0B | $2.1B |
| 总资产 | $5.9B | $4.1B |
| 负债/权益比越低杠杆越低 | 1.63× | — |
8季度趋势，按日历期对齐
现金及短期投资AMICUI
| Q1 26 | $180.4M | — | ||
| Q4 25 | $180.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $308.6M | ||
| Q3 24 | — | $312.5M | ||
| Q2 24 | — | $302.6M |
总债务AMICUI
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $3.1B | — | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — |
股东权益AMICUI
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $2.1B | ||
| Q3 25 | $2.1B | $2.1B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.1B | $2.0B | ||
| Q4 24 | $2.1B | $2.0B | ||
| Q3 24 | $2.1B | $2.0B | ||
| Q2 24 | $2.1B | $2.0B |
总资产AMICUI
| Q1 26 | $5.9B | — | ||
| Q4 25 | $5.9B | $4.1B | ||
| Q3 25 | $5.7B | $4.1B | ||
| Q2 25 | $5.7B | $4.1B | ||
| Q1 25 | $5.8B | $4.2B | ||
| Q4 24 | $5.8B | $4.2B | ||
| Q3 24 | $5.8B | $4.3B | ||
| Q2 24 | $5.8B | $4.3B |
负债/权益比AMICUI
| Q1 26 | 1.63× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.9M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $186.9M | $36.0M |
| 自由现金流率自由现金流/营收 | 64.2% | 6.6% |
| 资本支出强度资本支出/营收 | 11.1% | 4.6% |
| 现金转化率经营现金流/净利润 | 1.65× | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流AMICUI
| Q1 26 | $198.9M | — | ||
| Q4 25 | $255.5M | $60.6M | ||
| Q3 25 | $212.8M | $56.7M | ||
| Q2 25 | $265.2M | $11.2M | ||
| Q1 25 | $198.9M | $51.3M | ||
| Q4 24 | $232.7M | $40.2M | ||
| Q3 24 | $184.9M | $36.1M | ||
| Q2 24 | $215.8M | $82.0M |
自由现金流AMICUI
| Q1 26 | $186.9M | — | ||
| Q4 25 | — | $36.0M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | — | $-8.5M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | $184.3M | $16.2M | ||
| Q2 24 | $147.2M | $62.5M |
自由现金流率AMICUI
| Q1 26 | 64.2% | — | ||
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -1.5% | ||
| Q1 25 | — | 6.1% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | 68.3% | 2.7% | ||
| Q2 24 | 54.6% | 10.5% |
资本支出强度AMICUI
| Q1 26 | 11.1% | — | ||
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | 0.0% | 3.8% | ||
| Q3 24 | 0.2% | 3.4% | ||
| Q2 24 | 25.4% | 3.3% |
现金转化率AMICUI
| Q1 26 | 1.65× | — | ||
| Q4 25 | 4.92× | — | ||
| Q3 25 | 1.84× | — | ||
| Q2 25 | 2.13× | 0.32× | ||
| Q1 25 | 1.65× | — | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 2.51× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AM
| Gathering and compression–Antero Resources | $238.0M | 82% |
| Other | $52.3M | 18% |
| Water handling–third party | $505.0K | 0% |
| Gathering and compression–third party | $295.0K | 0% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
